NCT06361238 Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
| NCT ID | NCT06361238 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Condition | Delirium, Postoperative |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2024-11-19 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 260 participants in total. It began in 2024-11-19 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 60 years 2. Type 2 diabetes 3. Patients undergoing elective cardiac surgery Exclusion Criteria: 1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc 2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments 3. History of central nervous system damage or surgery 4. Cardiac function NYHA Class IV 5. Severe liver dysfunction (Child-Pugh Class C) 6. Severe renal failure requiring renal replacement therapy 7. History of pancreatitis 8. Type 1 diabetes 9. Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period 10. Patients with medullary thyroid carcinoma or a family history of it 11. Pregnant or breastfeeding women 12. Intolerance or allergy to liraglutide 13. Previous use of GLP-1A and SGLT2i 14. Patients who refuse to sign the informed consent
Contact & Investigator
Dongjin Wang, PhD，MD
PRINCIPAL INVESTIGATOR
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Frequently Asked Questions
Who can join the NCT06361238 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Delirium, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06361238 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 260 participants.
Is NCT06361238 currently recruiting?
Yes, NCT06361238 is actively recruiting participants. Contact the research team at diligent_hi@163.com for enrollment information.
Where is the NCT06361238 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06361238 clinical trial?
NCT06361238 is sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. The principal investigator is Dongjin Wang, PhD，MD at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University. The trial plans to enroll 260 participants.